Did the TRIIM study prove that humans can be rejuvenated?

No. TRIIM was a small pilot study without a control group, with 9–10 men. It reported a computed "rejuvenation" of a few years via epigenetic clocks – these are estimation markers, not hard endpoints such as life expectancy. It is a signal for further research, not proof.

Can I achieve the same effect with GH secretagogues or thymosin?

There is no evidence for that. TRIIM tested neither GH secretagogues (e.g., Sermorelin, Tesamorelin, CJC-1295/Ipamorelin) nor thymosin. Equating them is a community claim. Moreover, many of these substances are not approved for human use, or only for narrowly limited indications.

Are the agents used in TRIIM approved anti-aging medications?

No. Growth hormone and Metformin are prescription medicines for defined indications; DHEA is regulated differently depending on the country. The combination for "rejuvenation" is not approved as a therapy. Such questions belong in medical hands – PeptidLotse deliberately gives no dosages or usage regimens.

Longevity & Hormones7 min readLast reviewed: June 2026

Thymus Rejuvenation and the TRIIM Study: What a Small Pilot Trial Really Shows

As we age, the thymus gland shrinks – the organ where our T cells are shaped – a central driver of immune aging. The TRIIM study (Fahy et al., 2019) made headlines because, in a handful of men, a combination treatment pointed toward biological rejuvenation in both thymus function and several "epigenetic clocks." It sounds spectacular – and that is precisely why a sober look is worthwhile. It was a very small, uncontrolled pilot study with only nine to ten participants and no comparison group. This article explains in accessible terms what the thymus and immune aging are about, what the study actually measured, where its limits lie, and how the frequently cited link to GH secretagogues and thymosin should be understood.

Machine-assisted translation. The German original is the authoritative version.

Key points

The thymus regresses with age; this is regarded as a driver of immune aging – which is why thymus rejuvenation is a plausible research goal.
The TRIIM study was a very small, uncontrolled pilot study (9–10 men) with a combination of growth hormone, DHEA, and Metformin.
The reported "rejuvenation" of a few years rests on epigenetic clocks – surrogate markers, not hard health endpoints.
Without a control group and independent confirmation, the effect remains a hypothesis; the larger follow-up study TRIIM-X (NCT04375657) is underway.
Transferring this to GH secretagogues or thymosin is a community claim, not established by TRIIM; the substances used are not an approved anti-aging protocol.

The thymus and immune aging: why the organ is of interest at all

The thymus is a small organ behind the breastbone. It is where T cells mature – the immune cells that fend off infections, recognize degenerate cells, and keep the immune system in balance. From childhood onward, the thymus begins to regress (the technical term is thymic involution): functional tissue is gradually replaced by fat, and the production of new, "naive" T cells declines markedly with age.

This regression is regarded as an important building block of so-called immunosenescence – the age-related weakening and dysregulation of the immune system. Review articles describe a twofold problem here: on the one hand, defenses become weaker (e.g., against infections), and on the other, a chronic, low-grade tendency toward inflammation rises ("inflammaging"). The idea behind thymus rejuvenation is therefore intuitive: anyone who could preserve or partially restore the thymus's functional tissue might be addressing one root of immune aging.

T cells mature in the thymus – central to defense against infections, tumors, and autoimmunity
The thymus begins to regress from childhood onward; functional tissue gives way to fat
Thymic involution is regarded as a driver of immune aging (immunosenescence)

What the TRIIM study did

TRIIM stands for "Thymus Regeneration, Immunorestoration, and Insulin Mitigation." In this pilot study by Gregory Fahy and colleagues, published in 2019 in the journal Aging Cell, nine to ten healthy men (around 51–65 years old) received a combination of three substances over roughly one year: recombinant human growth hormone (rhGH) as the presumed stimulus for the thymus tissue, together with DHEA and Metformin, which were intended, among other things, to mitigate the diabetogenic (blood-sugar-raising) side effect of the growth hormone.

The thymus was measured by MRI (proportion of functional tissue versus fat), along with clinical and immunological markers as well as "biological age" via several epigenetic clocks – algorithms that estimate a computed age based on DNA methylation patterns. The study reported, in several participants, an improvement in the functional thymus proportion on MRI, as well as, on average, an epigenetic age that after one year was computationally about 1.5 to 2.5 years below the baseline value; part of this effect was still measurable a few months after the end of treatment. Importantly: these are algorithmically estimated markers, not direct proof of a longer or healthier life.

Very small pilot study: 9–10 healthy men, approx. 51–65 years old, about 12 months
Combination of recombinant growth hormone, DHEA, and Metformin
Endpoints: thymus MRI, immune and risk markers, epigenetic age clocks
Reported: computed "rejuvenation" of ~1.5–2.5 years and in part better thymus markers

How robust is the data really?

Here honesty is crucial. TRIIM was explicitly an exploratory pilot study – the authors themselves name the limits. The most important: there was no control or placebo group. Without a comparison, it cannot be cleanly separated what is due to the treatment and what is, for example, measurement variation, lifestyle changes, or chance. Added to this are the very small sample size, the exclusively male participants, and the fact that three active substances were given simultaneously – which share of which effect was caused by which remains open.

The epigenetic clocks are indeed interesting research tools, but they are surrogate markers: they estimate an age; they do not measure hard endpoints such as disease frequency or life expectancy. A computed rejuvenation of a few years in a tiny, uncontrolled group is a signal for further research – not proof of benefit. Precisely for this reason, a larger follow-up study, TRIIM-X (ClinicalTrials.gov NCT04375657, Phase 2), is underway, with more participants, both sexes, and – importantly – an active control arm. Until its results are available and independently confirmed, the rule is: a promising hypothesis, not a proven effect.

No control/placebo group – cause and effect cannot be cleanly separated
Very small, all-male sample; three active substances at the same time
Epigenetic clocks are surrogate markers, not hard health endpoints
Follow-up study TRIIM-X (NCT04375657) is underway – results pending

Regulatory status of the substances used

A common misunderstanding: TRIIM did not test an approved "rejuvenation drug." Each of the three components has its own clearly defined status. Recombinant growth hormone (Somatropin) is a prescription medicine approved for certain medical indications – use for "rejuvenation" in healthy people would be off-label and a matter of medical responsibility. Metformin is an approved, prescription-only diabetes medication; its anti-aging benefit in metabolically healthy people is the subject of separate studies and is not established. DHEA is regulated differently depending on the country – in some places prescription-only, in others sold as a dietary supplement – and is hormonally active.

The combination as an anti-aging protocol is neither approved as a therapy nor established as safe and effective for this purpose. PeptidLotse is a purely informational site and deliberately gives no dosages, regimens, or sources of supply. Anyone wishing to clarify such questions for themselves should do so medically – not least because growth hormone and hormone preparations carry relevant risks.

Somatropin (rhGH): prescription-only; anti-aging use would be off-label
Metformin: approved diabetes medication; longevity benefit unproven
DHEA: regulated differently by country (prescription or supplement), hormonally active
The combination is not an approved rejuvenation protocol

The bridge to GH secretagogues and thymosin – and the hype

In forums and marketing, the TRIIM idea is readily transferred to other substances. Two groups come up particularly often. First, GH secretagogues: instead of administering growth hormone directly, substances such as Sermorelin, Tesamorelin, or CJC-1295/Ipamorelin are supposed to prompt the body to release more of its own growth hormone. The community claim that this can be used one-to-one for thymus rejuvenation is exactly that: a claim. TRIIM did not test these secretagogues; the inference from "rhGH showed a signal" to "GH secretagogues rejuvenate the thymus" is not established. Tesamorelin is approved as a medicine only for a narrowly limited indication; several other secretagogues are not approved for human use.

Second, thymosin: Thymosin alpha-1 is an immunomodulating peptide used medicinally in some countries – its name refers to the thymus, which fuels the associative link with "thymus rejuvenation." Here too the rule applies: a direct role in epigenetic rejuvenation in the sense of TRIIM has not been demonstrated. Overall, the body of evidence is intriguing but thin: a small pilot signal, a great deal of extrapolation, little confirmation. The responsible approach remains to read this as early research – and to critically scrutinize any promises of salvation or rejuvenation.

GH secretagogues (e.g., Sermorelin, Tesamorelin, CJC-1295/Ipamorelin) were not tested in TRIIM
Transferring this to thymus rejuvenation is a community claim, not evidence
Thymosin alpha-1 is immunomodulating, but not a proven rejuvenation agent
Early research: yes to a signal, no to proof – scrutinize promises critically

Related substance profiles

Thymosin Alpha-1 (TA-1)

Immunomodulating peptide — approved as Zadaxin in several countries, not FDA-approved.

Tesamorelin

GHRH analogue — approved prescription-only in the USA (HIV lipodystrophy).

Sermorelin

GHRH analogue — was approved as Geref, today no approved finished medicinal product.

CJC-1295 + Ipamorelin

Growth hormone secretagogues — research peptides, not approved for humans.

Frequently asked questions

Did the TRIIM study prove that humans can be rejuvenated?: No. TRIIM was a small pilot study without a control group, with 9–10 men. It reported a computed "rejuvenation" of a few years via epigenetic clocks – these are estimation markers, not hard endpoints such as life expectancy. It is a signal for further research, not proof.
Can I achieve the same effect with GH secretagogues or thymosin?: There is no evidence for that. TRIIM tested neither GH secretagogues (e.g., Sermorelin, Tesamorelin, CJC-1295/Ipamorelin) nor thymosin. Equating them is a community claim. Moreover, many of these substances are not approved for human use, or only for narrowly limited indications.
Are the agents used in TRIIM approved anti-aging medications?: No. Growth hormone and Metformin are prescription medicines for defined indications; DHEA is regulated differently depending on the country. The combination for "rejuvenation" is not approved as a therapy. Such questions belong in medical hands – PeptidLotse deliberately gives no dosages or usage regimens.

Sources

This article is for information and education only. It does not replace medical advice and deliberately contains no dosing, usage or sourcing information.

← All guide articles